{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:59:31Z","timestamp":1790675971036,"version":"4.1.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disorder worldwide, characterized by a multifactorial pathogenesis involving genetic predisposition, metabolic disturbances, environmental influences, and gut microbiota interactions. In recent years, the gut microbiota has garnered significant attention for its pivotal role in MASLD development and progression through the gut-liver axis. This review comprehensively summarizes current understanding of the molecular mechanisms by which gut microbiota and their metabolites contribute to MASLD pathogenesis, including intestinal barrier dysfunction, bile acid metabolism dysregulation, abnormalities in short-chain fatty acid and tryptophan metabolism, oxidative stress, and mitochondrial impairment. Furthermore, we comprehensively discuss advances in therapeutic strategies targeting gut microbiota modulation, such as probiotics\/prebiotics, fecal microbiota transplantation, dietary interventions, bioactive compounds from traditional Chinese medicine, and surgical approaches. By integrating these insights, this review aims to provide novel perspectives for precise prevention and treatment of MASLD, highlighting the gut microbiota as a promising target for future clinical management.<\/jats:p>","DOI":"10.3389\/fmicb.2026.1971785","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:28:16Z","timestamp":1790674096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Deciphering the gut-liver axis in MASLD: from dysbiosis-driven pathogenesis to precision microbiome therapeutics"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenxin","family":"Liu","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lan","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]},{"name":"Department of Gastroenterology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University","place":["Lanzhou, China"]},{"name":"Department of Gastroenterology, The First Hospital of Lanzhou University","place":["Lanzhou, China"]},{"name":"Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"100397","DOI":"10.1016\/j.xcrm.2021.100397","article-title":"Lower brown adipose tissue activity is associated with non-alcoholic fatty liver disease but not changes in the gut microbiota","volume":"2","author":"Ahmed","year":"2021","journal-title":"Cell Rep Med."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in metabolic-associated Steatotic liver disease (MASLD)","volume":"16","author":"Bened\u00e9-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2631834","DOI":"10.1080\/19490976.2026.2631834","article-title":"Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut-liver crosstalk for clinical translation","volume":"18","author":"Bened\u00e9-Ubieto","year":"2026","journal-title":"Gut Microbes"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.tips.2024.05.004","article-title":"Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment","volume":"45","author":"Booijink","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e100204","DOI":"10.1136\/egastro-2025-100204","article-title":"Gut dysbiosis is linked to severe steatosis and enhances its diagnostic performance in MASLD","volume":"3","author":"Borges-Canha","year":"2025","journal-title":"eGastroenterology."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"Caussy","year":"2019","journal-title":"Nat. Commun."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.2147\/DMSO.S537001","article-title":"The effect of Semaglutide on gut microbiota in Chinese patients with type 2 diabetes poorly controlled by metformin","volume":"18","author":"Chen","year":"2025","journal-title":"Diabetes Metab Syndr Obes."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001721","article-title":"Dietary anthocyanins alleviate age-dependent hepatic steatosis by expanding Limosilactobacillus reuteri and modulating gut microbiota-bile acid-hepatic FXR signaling","author":"Chen","year":"2026","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"157348","DOI":"10.1016\/j.phymed.2025.157348","article-title":"Yuzhuo zhixiao pill can treat non-alcoholic steatohepatitis through modulation of gut microbiota, bile acid and short-chain fatty acid metabolism","volume":"148","author":"Du","year":"2025","journal-title":"Phytomedicine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J. Hepatol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2390164","DOI":"10.1080\/19490976.2024.2390164","article-title":"Time-restricted feeding ameliorates non-alcoholic fatty liver disease through modulating hepatic nicotinamide metabolism via gut microbiota remodeling","volume":"16","author":"Feng","year":"2024","journal-title":"Gut Microbes"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1007\/s13679-026-00694-8","article-title":"The role of butyrate in people with metabolic dysfunction-associated steatotic liver disease and related metabolic comorbidities: a systematic review","volume":"15","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2026","journal-title":"Curr. Obes. Rep."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2541035","DOI":"10.1080\/19490976.2025.2541035","article-title":"Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial","volume":"17","author":"Groenewegen","year":"2025","journal-title":"Gut Microbes"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"157987","DOI":"10.1016\/j.phymed.2026.157987","article-title":"Isorhamnetin alleviates diet induced MASLD in mice by modulating gut microbiota and bile acid metabolism","volume":"153","author":"Guo","year":"2026","journal-title":"Phytomedicine"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"113937","DOI":"10.1016\/j.intimp.2024.113937","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice","volume":"147","author":"Hu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"157608","DOI":"10.1016\/j.phymed.2025.157608","article-title":"Jiangtang tiaozhi formula alleviates obesity by enhancing adipose thermogenesis via TGR5-mediated gut-liver-adipose axis","volume":"150","author":"Hu","year":"2026","journal-title":"Phytomedicine"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3350\/cmh.2025.0718","article-title":"Pediatric metabolic dysfunction-associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation","volume":"32","author":"Jiang","year":"2026","journal-title":"Clin. Mol. Hepatol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1038\/s41598-026-36318-3","article-title":"Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake","volume":"16","author":"Klemets","year":"2026","journal-title":"Sci. Rep."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2226922","DOI":"10.1080\/19490976.2023.2226922","article-title":"Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies","volume":"15","author":"Koning","year":"2023","journal-title":"Gut Microbes"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"108184","DOI":"10.1016\/j.phrs.2026.108184","article-title":"Gut microbial extracellular vesicles modulate the development of metabolic dysfunction-associated steatohepatitis through the gut-liver axis","volume":"227","author":"Kwak","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","article-title":"Intestinal Virome signature associated with severity of nonalcoholic fatty liver disease","volume":"159","author":"Lang","year":"2020","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"9385","DOI":"10.1038\/s41598-020-66241-0","article-title":"Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools","volume":"10","author":"Lang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","article-title":"Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma","volume":"22","author":"Lau","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1136\/gutjnl-2025-336617","article-title":"Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health","volume":"75","author":"Lee","year":"2026","journal-title":"Gut"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2644677","DOI":"10.1080\/19490976.2026.2644677","article-title":"Gut microbiome and metabolic health: mechanisms and precision interventions","volume":"18","author":"Li","year":"2026","journal-title":"Gut Microbes"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1735669","DOI":"10.3389\/fnut.2026.1735669","article-title":"Targeting the gut microbiota: the application and prospects of probiotics, fecal microbiota transplantation, and natural products in MASLD","volume":"13","author":"Li","year":"2026","journal-title":"Front. Nutr."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001417","article-title":"Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): current knowledge of mechanisms","author":"Liu","year":"2025","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41522-023-00399-z","article-title":"Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism","volume":"9","author":"Liu","year":"2023","journal-title":"NPJ Biofilms Microbiomes"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.crfs.2025.101138","article-title":"Probiotics as a therapeutic strategy for metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"11","author":"Lu","year":"2025","journal-title":"Curr Res Food Sci."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.chom.2025.04.020","article-title":"Gut microbial enzymes and metabolic dysfunction-associated steatohepatitis: function, mechanism, and therapeutic prospects","volume":"33","author":"Luo","year":"2025","journal-title":"Cell Host Microbe"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"154595","DOI":"10.1016\/j.phymed.2022.154595","article-title":"Platycodon grandiflorus root extract activates hepatic PI3K\/PIP3\/Akt insulin signaling by enriching gut Akkermansia muciniphila in high fat diet fed mice","volume":"109","author":"Luo","year":"2023","journal-title":"Phytomedicine"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"157517","DOI":"10.1016\/j.phymed.2025.157517","article-title":"Gut-liver axis mechanisms of Hippophae rhamnoides L. in non-alcoholic fatty liver disease prevention","volume":"149","author":"Ma","year":"2025","journal-title":"Phytomedicine"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"106098","DOI":"10.1016\/j.ebiom.2025.106098","article-title":"Reprogramming offspring liver health: maternal indole supplementation as a preventive strategy against MASLD","volume":"123","author":"Mandala","year":"2026","journal-title":"EBioMedicine"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2307568","DOI":"10.1080\/19490976.2024.2307568","article-title":"Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation","volume":"16","author":"Min","year":"2024","journal-title":"Gut Microbes"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.3390\/nu16234198","article-title":"Sex-dependent gut microbiota features and functional signatures in metabolic Disfunction-associated Steatotic liver disease","volume":"16","author":"Mogna-Pel\u00e1ez","year":"2024","journal-title":"Nutrients"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2580773","DOI":"10.1080\/07853890.2025.2580773","article-title":"ACT001 alleviates MASLD through gut microbiota-bile acid-FXR axis in mice","volume":"57","author":"Niu","year":"2025","journal-title":"Ann. Med."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3350\/cmh.2024.0359","article-title":"Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments","volume":"31","author":"Pirola","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e14830","DOI":"10.1002\/advs.202514830","article-title":"Gut Mycobiota-associated tryptophan catabolites protect against metabolic dysfunction-associated Steatotic liver disease","volume":"13","author":"Qiao","year":"2026","journal-title":"Adv Sci (Weinh)."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"100216","DOI":"10.1016\/j.mocell.2025.100216","article-title":"Intestinal bacteria-derived extracellular vesicles in metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics","volume":"48","author":"Qin","year":"2025","journal-title":"Mol. Cells"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","article-title":"Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Saeed","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40168-024-02004-7","article-title":"Characterization of liver, adipose, and fecal microbiome in obese patients with MASLD: links with disease severity and metabolic dysfunction parameters","volume":"13","author":"Schwenger","year":"2025","journal-title":"Microbiome."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3390\/microorganisms9102118","article-title":"Sex-specific associations between gut microbiome and non-alcoholic fatty liver disease among urban Chinese adults","volume":"9","author":"Shi","year":"2021","journal-title":"Microorganisms."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/apt.16602","article-title":"Review article: therapeutic aspects of bile acid signalling in the gut-liver axis","volume":"54","author":"Simbrunner","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2223330","DOI":"10.1080\/19490976.2023.2223330","article-title":"Faecal microbiota transplantation affects liver DNA methylation in non-alcoholic fatty liver disease: a multi-omics approach","volume":"15","author":"Stols-Gon\u00e7alves","year":"2023","journal-title":"Gut Microbes"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1562896","DOI":"10.3389\/fphar.2025.1562896","article-title":"Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice","volume":"16","author":"Sun","year":"2025","journal-title":"Front. Pharmacol."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1038\/s41401-024-01303-x","article-title":"A new mechanism of thyroid hormone receptor \u03b2 agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles","volume":"45","author":"Sun","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"ref54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13679-025-00657-5","article-title":"The intriguing roles of cytokines in metabolic dysfunction-associated steatotic liver disease: a narrative review","volume":"14","author":"Vachliotis","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"G485","DOI":"10.1152\/ajpgi.00362.2020","article-title":"Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?","volume":"320","author":"Villard","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1111\/dom.70571","article-title":"Post-semaglutide weight regain in females with obesity: associations with gut microbiota, bile acid metabolism, and central nervous system","volume":"28","author":"Wang","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12967-025-07443-w","article-title":"Characterization of the gut virome in patients with nonalcoholic fatty liver disease","volume":"24","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"152161","DOI":"10.1016\/j.bbrc.2025.152161","article-title":"Multi-omics approaches to explore the therapeutic mechanism for ginsenoside Rg1 against MASLD","volume":"776","author":"Wang","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12986-025-00939-8","article-title":"Inverse associations between Mediterranean diet constituents and the gut microbiota in metabolic-associated steatotic liver disease (MASLD): a case-control study","volume":"23","author":"Williams","year":"2025","journal-title":"Nutr. Metab. (Lond.)"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"2500099","DOI":"10.1080\/19490976.2025.2500099","article-title":"Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Wu","year":"2025","journal-title":"Gut Microbes"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"102397","DOI":"10.1016\/j.clinre.2024.102397","article-title":"Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Wu","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3350\/cmh.2024.0315","article-title":"Immunological mechanisms in steatotic liver diseases: an overview and clinical perspectives","volume":"30","author":"Yan","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41522-026-01037-0","article-title":"Faecalibacterium-derived spermidine mediates the amelioration of fatty liver hemorrhagic syndrome by inulin in laying hens","volume":"12","author":"Yang","year":"2026","journal-title":"NPJ Biofilms Microbiomes"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/ph19040557","article-title":"Unraveling the mechanisms of Wuling powder against MASLD by integrated metabolomics-gut microbiota-serum Pharmacochemistry","volume":"19","author":"Yang","year":"2026","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"123967","DOI":"10.1016\/j.biomaterials.2025.123967","article-title":"Kudzu root-derived carbon dots modulate gut microbiota and metabolites for pan-organ targeted macrophage polarization in synergistic diabetes therapy","volume":"329","author":"Yi","year":"2026","journal-title":"Biomaterials"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"156992","DOI":"10.1016\/j.phymed.2025.156992","article-title":"Alisol B ameliorated metabolic dysfunction-associated steatotic liver disease via regulating purine metabolism and restoring the gut microbiota disorders","volume":"145","author":"Yiyou","year":"2025","journal-title":"Phytomedicine"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3350\/cmh.2023.0291","article-title":"Waiting for the changes after the adoption of steatotic liver disease","volume":"29","author":"Yoon","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.7150\/ijbs.54604","article-title":"Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver","volume":"17","author":"Yu","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"154444","DOI":"10.1016\/j.phymed.2022.154444","article-title":"Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling","volume":"107","author":"Zhai","year":"2022","journal-title":"Phytomedicine"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2508433","DOI":"10.1080\/19490976.2025.2508433","article-title":"Bacteroides uniformis-generated hexadecanedioic acid ameliorates metabolic-associated fatty liver disease","volume":"17","author":"Zhang","year":"2025","journal-title":"Gut Microbes"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jhep.2024.08.008","article-title":"Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids","volume":"82","author":"Zhang","year":"2025","journal-title":"J. Hepatol."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1186\/s12866-025-04348-y","article-title":"Characterization of the gut mycobiome in patients with non-alcoholic fatty liver disease and correlations with serum metabolome","volume":"25","author":"Zheng","year":"2025","journal-title":"BMC Microbiol."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2372881","DOI":"10.1080\/19490976.2024.2372881","article-title":"Washed microbiota transplantation promotes homing of group 3 innate lymphoid cells to the liver via the CXCL16\/CXCR6 axis: a potential treatment for metabolic-associated fatty liver disease","volume":"16","author":"Zhong","year":"2024","journal-title":"Gut Microbes"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"157140","DOI":"10.1016\/j.phymed.2025.157140","article-title":"Geniposidic acid alleviated metabolic dysfunction-associated steatotic liver disease by exciting SIRT6 signaling","volume":"146","author":"Zhou","year":"2025","journal-title":"Phytomedicine"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"100120","DOI":"10.1016\/j.pharmr.2026.100120","article-title":"Gut microbiome and bile acid metabolism in liver disease: mechanisms, clinical implications, and therapeutic opportunities","volume":"78","author":"Zhou","year":"2026","journal-title":"Pharmacol. Rev."},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-71981-0","article-title":"Multi-kingdom profiling reveals altered gut phage-bacteria-metabolite interactions in MASLD","volume":"17","author":"Zhou","year":"2026","journal-title":"Nat. Commun."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2508951","DOI":"10.1080\/19490976.2025.2508951","article-title":"Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH","volume":"17","author":"Z\u00f6ggeler","year":"2025","journal-title":"Gut Microbes"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1971785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:28:18Z","timestamp":1790674098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1971785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":78,"alternative-id":["10.3389\/fmicb.2026.1971785"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1971785","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1971785"}}